Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications-Reference-Cited by-同舟云学术

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications

Published:2018-10-18 Issue:2 Volume:28 Page:
ISSN:0962-1105
Container-title:Journal of Sleep Research
language:en
Short-container-title:J Sleep Res

Author:

Herring W. Joseph¹^ORCID,Roth Thomas²,Krystal Andrew D.³,Michelson David¹

Affiliation:

1. Clinical ResearchMerck & Co., Inc. Kenilworth New Jersey USA

2. Sleep Disorders and Research Center Henry Ford Hospital Detroit MI USA

3. Department of Psychiatry University of California San Francisco California USA

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Behavioral Neuroscience,Cognitive Neuroscience,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jsr.12782

Reference131 articles.

1. Neural substrates of awakening probed with optogenetic control of hypocretin neurons

2. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey I;Ancoli‐Israel S.;Sleep,1999

3. The interim report about the drug use‐results survey of orexinergic receptor antagonist, Belsomra, in patients with insomnia;Asai Y.;Japanese Journal of Sleep Medicine,2017

4. Sleep changes in the disorder of insomnia: A meta-analysis of polysomnographic studies

5. Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual orexin receptor antagonist ameliorates sleep deprivation-induced learning and memory impairment in APP/PS1 mice;Sleep Medicine;2024-09

2. Cannabinoid and Orexigenic Systems Interplay as a New Focus of Research in Alzheimer’s Disease;International Journal of Molecular Sciences;2024-05-15

3. Insomnia medications: History, characteristics, and guidelines for optimal use in clinical practice;Journal of Sleep Research;2023-11-08

4. Synthesis and clinical application of new drugs approved by FDA in 2022;Molecular Biomedicine;2023-09-04

5. Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy;Neuropeptides;2023-06